Francesco Grimaldi

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Journal: Haematologica

Published: January 14, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report.

Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report.

Journal: International journal of molecular sciences

Published: November 26, 2025

Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series.

Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series.

Journal: Annals of hematology

Published: October 03, 2025

Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study.

Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study.

Journal: Infectious diseases (London, England)

Published: September 05, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: July 29, 2025

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Real-life management of 476 older adults with Philadelphia-negative acute lymphoblastic leukemia: a Campus ALL study.

Journal: Haematologica

Published: June 25, 2025

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.

Journal: Annals of hematology

Published: May 30, 2025

Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts.

Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts.

Journal: Blood neoplasia

Published: May 30, 2025

Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center.

Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center.

Journal: Cancers

Published: May 27, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances

Published: May 19, 2025

Showing 1-12 of 43

Last Updated: 09/26/2026